成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

TICAGRELOR

TICAGRELOR Struktur
274693-27-5
CAS-Nr.
274693-27-5
Englisch Name:
TICAGRELOR
Synonyma:
Brilinta;(1S,2S,3R,5S)-3-(7-(((1R,2S)-2-(4-fluoro-3-(methylthio)phenyl) cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol;AZ13265501;Ticargrelor;Tecagrelor;Ticagrelore;Bentracimab;Ticag;Tigre;Possia
CBNumber:
CB51509134
Summenformel:
C23H28F2N6O4S
Molgewicht:
522.57
MOL-Datei:
274693-27-5.mol

TICAGRELOR Eigenschaften

Schmelzpunkt:
138-140°C
Siedepunkt:
777.6±70.0 °C(Predicted)
Dichte
1.67
storage temp. 
Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
L?slichkeit
Methanol (Slightly)
pka
13.26±0.70(Predicted)
Aggregatzustand
Solid
Farbe
White to Off-White
Stabilit?t:
Hygroscopic
InChIKey
OEKWJQXRCDYSHL-FNOIDJSQSA-N
SMILES
[C@@H]1(O)[C@@H](OCCO)C[C@@H](N2C3C(N=N2)=C(N[C@@H]2C[C@H]2C2=CC=C(F)C(F)=C2)N=C(SCCC)N=3)[C@@H]1O
Sicherheit
  • Risiko- und Sicherheitserkl?rung
  • Gefahreninformationscode (GHS)
S-S?tze: 24/25
HS Code  29335990
Giftige Stoffe Daten 274693-27-5(Hazardous Substances Data)
Bildanzeige (GHS) GHS hazard pictogramsGHS hazard pictograms
Alarmwort Warnung
Gefahrenhinweise
Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code
H319 Verursacht schwere Augenreizung. Schwere Augenreizung Kategorie 2 Warnung GHS hazard pictogramssrc="/GHS07.jpg" width="20" height="20" /> P264, P280, P305+P351+P338,P337+P313P
H411 Giftig für Wasserorganismen, mit langfristiger Wirkung. Langfristig (chronisch) gew?ssergef?hrdend Kategorie 2
Sicherheit
P264 Nach Gebrauch gründlich waschen.
P264 Nach Gebrauch gründlich waschen.
P280 Schutzhandschuhe/Schutzkleidung/Augenschutz tragen.
P305+P351+P338 BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach M?glichkeit entfernen. Weiter spülen.

TICAGRELOR Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

In December 2010, the P2Y12 receptor antagonist ticagrelor (also known as AZD6140) was approved in Europe for the treatment of acute coronary syndrome (ACS), a condition that covers several clinical symptoms with the potential to cause acute myocardial ischemia (MI). ADP binds to two purinergic receptors, the P2Y1 and P2Y12 receptors. The action of ADP binding to the P2Y12 receptor results in activation of the GP Ⅱb/Ⅲa (integrin) receptor.GP Ⅱb/Ⅲa initiates and prolongs platelet aggregation, which in turn results in the cross-linking of platelets through fibrin and finally thrombus formation. Inhibition of ADP stimulation of the P2Y12 receptor has been found to be an effective strategy for managing the atherothrombotic events associated with ACS and potentially resulting from percutaneous coronary intervention (PCI, stent implantation) .

Chemische Eigenschaften

White Solid

Definition

ChEBI: A triazolopyrimidine that is an adenosine isostere; the cyclopentane ring is similar to ribose and the nitrogen-rich [1,2,3]triazolo[4,5-d]pyrimidine moiety resembles the nucleobase adenine. A platelet aggregation inhibitor which is used for p evention of thromboembolic events in patients with acute coronary syndrome.

Clinical Use

Ticagrelor, discovered and developed by AstraZeneca, is a platelet adenosine diphosphate (ADP) P2Y12 (P2T) reversible receptor antagonist approved in the E.U. in 2010 and launched in Germany and the UK in 2011 for the treatment of patients with acute coronary syndromes (ACS). It was approved in the U.S. and Canada in 2011 following successful clinical trial results in patients with ACS which showed it to be superior to preexisting drugs for reducing death due to vascular causes. Ticagrelor is an oral drug indicated for use in combination with acetylsalicylic acid (aspirin) for the prevention of atherothrombotic events in adult patients with ACS (unstable angina, non-ST elevation myocardial infarction (NSTEMI), or ST elevation myocardial infarction (STEMI)). Unlike its competitors prasugrel and clopidogrel, which require bioactivation, ticagrelor is not a prodrug and does not require in vivo activation. It has a rapid onset of action, relatively rapid reversibility, greater potency, and exhibits consistency in platelet inhibition. Following dosing, ticagrelor reaches Cmax in about 1.5 h, with formation of a major metabolite with equipotent intrinsic activity to the parent compound.

TICAGRELOR Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


TICAGRELOR Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Global( 668)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
AFINE CHEMICALS LIMITED
+86-0571-85134551
sales@afinechem.com China 15352 58
Hebei Weibang Biotechnology Co., Ltd
+8615531157085
abby@weibangbio.com China 8810 58
Hebei Chuanghai Biotechnology Co,.LTD
+86-13131129325
sales1@chuanghaibio.com China 5889 58
XuZhou Magic Biotechnology Co., Ltd.
+undefined13921770081
SVP01@magicbiotech.cn China 92 58
shandong perfect biotechnology co.ltd
+86-53169958659 +86-13153181156
sales@sdperfect.com China 294 58
Henan Bao Enluo International TradeCo.,LTD
+86-17331933971 +86-17331933971
deasea125996@gmail.com China 2472 58
Henan Fengda Chemical Co., Ltd
+86-371-86557731 +86-13613820652
info@fdachem.com China 20284 58
Shaanxi TNJONE Pharmaceutical Co., Ltd
+8618092446649
sarah@tnjone.com China 1143 58
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
+86-18600796368 +86-18600796368
sales@sjar-tech.com China 456 58
Capot Chemical Co.,Ltd.
+86-(0)57185586718 +86-13336195806
sales@capot.com China 29791 60

274693-27-5()Verwandte Suche:


  • 1,2-Cyclopentanediol, 3-[7-[[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-, (1S,2S,3R,5S)-
  • Ticagrelor, >=98%
  • Ticagrelo
  • Ticarelor
  • Brilique
  • (1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino]-5-propylsulfanyltriazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
  • TICAGRELOR
  • (1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-1,2-cyclopentanediol
  • Azd 6140
  • Unii-glh0314rvc
  • (1S,2S,3R,5S)-3-(7-(((1S,2S)-2-(3,4-difluorophenyl)cyclopropyl)aMino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyriMidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
  • AR-C 126532XX
  • Ticagrelor(AR-C 126532XX
  • Ticagrelor (AZD6140)
  • (1S,2S,3R,5S)-3-(7-((1R,2S)-2-(3,4-difluorophenyl)cyclopropylaMino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyriMidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
  • (1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-D1,2-Cyclopentanediolifluorophenyl)cyclopropyl]aMino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyriMidin-3-yl]-5-(2-hydroxyethoxy)-1,2-cyclopentanediol
  • 3-[7-[[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]aMino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyriMidin-3-yl]-5-(2-hydroxyethoxy)-,(1S,2S,3R,5S)-
  • (1S,2S,3R,5S)-3-[7-[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropylaMino]-5-(propylsulfanyl)-3H-[1,2,3]triazolo[4,5-d]pyriMidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
  • Possia
  • Ticagrelor and intermediates
  • Ticagrelor Standards
  • Tikagre
  • Ticagrel
  • Ticagrelor Impurity 81
  • Ticagrelor (Brilinta,AZD6140)
  • CS-256
  • AZD-6140; TICAGRELOR ; BRILINTA; AZD 6140
  • 1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
  • Ticagrelor standard
  • Ticag
  • (1S,2S,3R,5S)-3-(7-(((1R)-2-(3,4-Difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3h-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
  • icagrelor
  • TICAGRELOR USP/EP/BP
  • Ticagrelor Form Ⅱ
  • (1S,2S,3R,5S)-3-[7-[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropy...
  • Ticagrelor for system suitability (Y0002223)Q: What is Ticagrelor for system suitability (Y0002223) Q: What is the CAS Number of Ticagrelor for system suitability (Y0002223)
  • TicagrelorQ: What is Ticagrelor Q: What is the CAS Number of Ticagrelor Q: What is the storage condition of Ticagrelor Q: What are the applications of Ticagrelor
  • Ticargrelor
  • Brilinta
  • (1S,2S,3R,5S)-3-(7-(((1R,2S)-2-(4-fluoro-3-(methylthio)phenyl) cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
  • AZ13265501
  • Ticagrelore
  • Bentracimab
  • Tecagrelor
  • Tigre
  • Research Grade Bentracimab (DGK10801)
  • Tegrelo
  • Ticagagrel
  • Ticagrelor IP/BP/EP
  • Tigrillo
  • Ticagrelor Form Ⅱ
  • Ticagrelor IP
  • 274693-27-5
  • 374693-27-5
  • 74693-27-5
  • C23H28F2N6O4S
  • AZD6140
  • Ticagrelor
Copyright 2019 ? ChemicalBook. All rights reserved